Evidence map›Paper›PMID 39932777›Full record

Trial reportCancer2025

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505.

Sameer H Patel, Sarah Colby, Davendra Sohal, Katherine A Guthrie, Lisa A Kachnic, E Gabriela Chiorean, Andrew M Lowy, Flavio G Rocha, Howard S Hochster, Philip A Philip and 1 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sameer H PatelDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-6442-1857
Sarah ColbySWOG Statistical and Data Management Center, Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA.
Davendra SohalDepartment of Medical Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Katherine A GuthrieSWOG Statistical and Data Management Center, Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA.
Lisa A KachnicDepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA.
E Gabriela ChioreanDepartment of Medicine, Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA.
Andrew M LowyDivision of Surgical Oncology, University of California, San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-7106-0735
Flavio G RochaDivision of Surgical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Howard S HochsterGastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Philip A PhilipOncology and Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Syed A AhmadDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888NIH HHS U10CA180819NIH HHS U10CA180888
6 · The paper itself

Abstract

backgroundChemotherapy is required to improve the overall survival (OS) of patients with resectable pancreatic ductal adenocarcinoma (PDAC). Assessing the impact of chemotherapy dose density (DD) on survival is difficult as a result of confounding. The objective of this study was to determine the impact of chemotherapy DD on OS in patients with resectable PDAC.

methodsThis was a secondary analysis of SWOG 1505, a randomized phase 2 trial of perioperative chemotherapy in resectable PDAC. DD was defined as the percentage of chemotherapy dose received of the total planned. Two landmark time points for OS were used: after surgery and at 40 weeks (which encompassed the entire treatment period).

resultsOf the 102 eligible patients enrolled, 73 (71%) underwent surgery, and median preoperative chemotherapy DD was 89%. Patients with ≥85% DD had higher OS compared to those with <85% DD (median, 38.1 vs. 17.2 months; p = .039). Of the 82 patients who survived to 40 weeks postrandomization, 67 underwent surgery, and median DD for all perioperative chemotherapy was 67%. In this cohort, DD ≥70% was associated with better OS (median, 32.2 vs. 14.0 months; p = .017). Perioperative DD was not significantly associated with pathologic response, margin status, or lymph node negativity.

conclusionsThis is the first study to identify a prognostic association of chemotherapy DD with OS in patients undergoing perioperative chemotherapy and surgery for resectable PDAC. Patients who received ≥85% DD preoperatively and/or ≥70% DD perioperatively survived longer than those receiving a smaller proportion of protocol therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedPrognosischemotherapydose densitypancreatic adenocarcinomasurgery

Identifiers

PMID39932777
PMCPMC11812894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.